Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathy Giorgio Cazzaniga, Maurizio Carbone, Raffaella Barretta, Gabriele Casati, Simona Vatrano, Giovanni Gambaro, Gisella Vischini, Irene Capelli, Renzo Mignani, Gianandrea Pasquinelli, Federico Pieruzzi, Leonardo Caroti, Egrina Dervishi, Marco Allinovi, Luca Novelli, Antonio Pisani, Albino Eccher, Fabio Pagni, Vincenzo L’Imperio Scientific Reports, 2026 Fabry disease (FD) is a rare lysosomal storage disorder caused by mutations in the GLA gene, resulting in globotriaosylceramide accumulation. Kidney involvement (Fabry nephropathy) significantly contributes to morbidity and mortality. Diagnosis can be difficult, especially in females or late-onset variants. Renal biopsy remains essential, but interpretation requires expert pathologists. Digital pathology and artificial intelligence (AI) offer promising solutions to support diagnosis. The study analyzed Whole-slide images from renal biopsies of Fabry nephropathy patients to develop and validate a “foamy podocytes” screening AI tool. Two computational tasks were performed: glomerular-level classification, and podocyte-level segmentation. Performance was evaluated using standard metrics. A novel ZEBRA score (fpA/tgA%) was developed to quantify disease burden, and correlations with histological scores and clinical parameters were assessed. EfficientNetB2 achieved the highest classification accuracy (79%) in identifying foamy podocytes. SegFormerB4 had the best segmentation performance (Dice = 0.46, IoU = 0.37). The ZEBRA score effectively distinguished Fabry nephropathy from controls ( p < 0.001) and showed good correlation with manual scoring (rs = 0.66–0.71). The AI-assisted ZEBRA pipeline highlights high-risk Fabry nephropathy features to support nephropathologists as a screening tool.
Prognostic role of myocardial storage, hypertrophy, and inflammation/fibrosis in Fabry cardiomyopathy: a new predictive score including T1 values Antonia Camporeale, Gianluigi Guida, Maurizio Pieroni, Federico Pieruzzi, Paola Lusardi, Marta Ferraresi, Laura Econimo, Alessandro Burlina, Renzo Mignani, Francesca Graziani, Valentina Milani, Federico Ambrogi, Lara Tondi, Giandomenico Disabato, Andrea Attanasio, Giada De Angeli, Kelvin Chow, Pietro Spagnolo, Gianpaolo Carrafiello, Massimo Lombardi European Heart Journal Quality of Care and Clinical Outcomes, 2026 Aims Limited data exist about the prognostic significance of the processes underlying Fabry Disease (FD) cardiomyopathy (storage, hypertrophy, inflammation/fibrosis) as detected by cardiac magnetic resonance (CMR). Notably, T1 mapping has had limited prognostic application primarily due to poor reproducibility across different sequences and vendors. This CMR study aimed to identify the prognostic weight of the different mechanisms of FD cardiomyopathy and to develop a predictive score of adverse cardiovascular (CV) events. Methods and results This prospective, observational study enrolled 167 FD patients, who underwent CMR at baseline. The study endpoint was the composite of all-cause death, heart failure hospitalization, new-onset atrial fibrillation/flutter, non-sustained/sustained ventricular tachycardia, major bradyarrhythmias, and myocardial infarction with non-obstructive coronary arteries. Over a median follow-up of 40 months, 27 patients (16%) experienced the primary endpoint. Left ventricle mass index (LVMI) [HR 1.02 (1.02–1.03), P &lt; 0.001], presence of late gadolinium enhancement (LGE) [HR 20.12 (6.02–67.24), P &lt; 0.001] and its extent [number of LGE + segments: HR 1.51 (1.33–1.71), P &lt; 0001], and septal T1 [HR 0.98 (0.97–0.99), &lt;0.001], measured in both ShMOLLI and MOLLI sequences, were associated with the composite endpoint. None of the patients with normal T1 experienced adverse CV events. A multivariable model including age, LVMI, number of LGE+ segments, and T1 value showed a good performance in predicting the composite endpoint. Conclusion We propose a 3-year prognostic score to predict CV outcome in FD, including age, LVMI, number of LGE+ segments, and septal T1. Normal T1 has a negative predictive value for adverse CV events irrespective of the acquisition setting.
Cardiopulmonary and skeletal muscle strategies underlying exhaustive exercise in adults with glycogen storage disease type III F. Lanfranconi, L. Peli, L. Pollastri, A. Ferri, L. Tremolizzo, E. Conti, F. Pieruzzi, G. Miserocchi, E. Beretta, M. Marzorati, W. Zardo, S. Gasperini, R. Pretese, S. Paci, C. Capelli, R. Mariani, A. Cattoni, A. C. Balduzzi, R. Parini Physiological Reports, 2026 People with glycogen storage disease type III (GSDIII‐p) have a remarkably reduced exercise tolerance. Aim of this study was to analyze the oxygen transport‐utilization chain strategies adopted by GSDIII‐p during exercise. Nine GSDIII‐p (39.4 ± 10.0 year, 33% female) and 11 healthy controls (CTRL), age and gender matched, underwent an incremental cardiopulmonary exhaustion test (CPET) to assess peak heart rate (HR), blood lactate [La]p and vastus lateralis O 2 fractional extraction (ΔHHb/isch) using near‐infrared spectroscopy. Patterns of breathing (PBr) were assessed accordingly by analyzing pulmonary O 2 uptake (V̇O 2 ), tidal volume (Vt), respiratory frequency (Rf), end‐tidal CO 2 (PETCO 2 ) and alveolar ventilation (V̇A). GSDIII‐p exhibited significantly ( p < 0.05) lower peak values of V̇O 2 , pulmonary ventilation (V̇E) [La] and ΔHHb/isch compared to CTRL (1.7 ± 0.7 vs. 3.2 ± 1.1 L/min, 50.5 ± 19.8 vs. 113.6 ± 40.4 L/min, 1.8 ± 0.7 vs. 7.6 ± 3.0 mmol/L and 39.1% ± 9.9% vs. 74.8% ± 36.6%, respectively). The range of peak V̇O 2 values for GSDIII‐p, compared to the predicted values for age and sex, was between 79% and 35%. Both GSDIII‐p and CTRL were arbitrarily divided into 4 groups according to individual V̇E values. GSDIII‐p with exercise intolerance relied on increased Rf with inadequate Vt adaptation to maintain V̇E and reduce PETCO 2 , with low V̇A values and low to moderate workloads tolerance. Reduced exercise tolerance in GSDIII‐p is related to respiratory and skeletal muscle inefficiencies. GSDIII‐p strong heterogeneity evaluated throught CPET provides insights into clinical management.
Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis Eleonora Riccio, Ivana Capuano, Pasquale Buonanno, Guido Iaccarino, Calogero Lino Cirami, Renzo Mignani, Federico Pieruzzi, Antonio Pisani Clinical Kidney Journal, 2025 Background A treatment for classic Fabry disease (FD) should be defined effective on renal function when it maintains a decline of estimated glomerular filtration rate (eGFR) &lt;1 ml/min/1.73 m2/year, and not effective when the eGFR loss remains ≥3 ml/min/1.73 m2/year. Therefore, considering the evidence of dose-dependent efficacy of the enzyme replacement therapy (ERT) and the data reporting the disease progression after switching form agalsidase beta to migalastat, a switch to higher doses of ERT should be considered in adult Fabry patients who have an eGFR of 45–90 ml/min/1.73 m2, with an eGFR slope ≥3 ml/min/1.73 m2/year. This study aimed to assess the effects of switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy. Methods Data retrospectively taken during the pre-switch period were compared with data prospectively collected during the post-switch period. The primary endpoint was the effect on eGFR slope. Secondary endpoints were: changes in clinical events, 24-hour proteinuria, cardiac and neurologic parameters, FD-related symptoms, lyso-Gb3 plasma concentrations, and adverse events. Results In total, 11 patients (nine males and two females) switched to agalsidase beta from 55.3 ± 31.2 months of primary therapy with agalsidase alfa (eight patients) or migalastat (three patients), were evaluated for a follow-up period of 24 months. After the switch, a significant reduction of the eGFR slope was observed (−4.61 vs −0.45 ml/min/1.73 m2/year, respectively in pre- and post-switch period; Ppost/pre &lt; .005). After the switch, plasma lyso-Gb3 levels progressively reduced, and the reduction reached the significance vs baseline at T2 (P &lt; .05). Most of FD-related symptoms ameliorated during the primary Fabry therapy and remained stable after the switch. All other parameters were stable over time. Conclusions Treatment switch from agalsidase alfa or migalastat to agalsidase beta can attenuate eGFR decline and enhance lyso-Gb3 reduction, confirming the dose-dependent effect of agalsidase beta to further slow down FD progression.
The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology Sandro Feriozzi, Yuri Battaglia, Calogero Lino Cirami, Concetta Gangemi, Gaetano La Manna, Loreto Gesualdo, Maria Lorenza Muiesan, Antonello Pani, Federico Pieruzzi, Flavio Ribichini, Stefano Taddei, Stefano Bianchi Journal of Nephrology, 2025 Hypertension is a clinical condition associated with an increase in cardiovascular morbidity and mortality. In chronic kidney disease (CKD), hypertension is also a driver of faster disease progression. Correct and appropriate treatment with antihypertensive medication reduces the risk of cardiovascular events and slows kidney disease progression. However, not all hypertensive patients achieve the desired blood pressure goals despite multiple antihypertensive therapies, and these are defined as patients with uncontrolled or resistant hypertension. Renal denervation has been successfully proposed to mitigate the hyperactivity of the sympathetic nervous system in patients with uncontrolled/resistant hypertension. The guidelines of the European Society of Cardiology and the European Society of Hypertension include renal denervation as a therapeutic option for treating hypertension in patients with uncontrolled or resistant hypertension. However, in patients with CKD, diffusion of the procedure has been limited by concerns over possible adverse effects on kidney function. Over the last few years, the improvement of the device-based procedure and the growing experience accumulated in several Nephrology centers have increased the use of renal denervation in patients with CKD. In patients with uncontrolled/resistant hypertension with a significant reduction of glomerular filtration rate (< 40 ml/min/1.73 m2), on dialysis, or living with a kidney transplant, the procedure significantly reduces blood pressure values over time without negative effects on kidney function. Taking into account the effectiveness of renal denervation in patients with uncontrolled or resistant hypertension and CKD, and the lack of defined indications concerning renal denervation in CKD, the Italian Society of Nephrology has decided to publish a position paper reviewing the available evidence in the medical literature. Graphical abstract
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial Duvuru Geetha, Christian Pagnoux, Sebastian E Sattui, Peter A Merkel, Maria Weiner, Juliana Draibe, Stanislas Faguer, Sarah Bray, Rachel E Gurlin, Monica Balcells-Oliver, Annette Bruchfeld, David R Jayne, , C Au Peh, A Chakera, B Cooper, J Kurtkoti, D Langguth, V Levidiotis, G Luxton, P Mount, D Mudge, E Noble, R Phoon, D Ranganathan, A Ritchie, J Ryan, M Suranyi, A Rosenkranz, K Lhotta, A Kronbichler, N Demoulin, C Bovy, R Hellemans, J Hougardy, B Sprangers, K Wissing, C Pagnoux, S Barbour, S Brachemi, S Cournoyer, L Girard, L Laurin, P Liang, D Philibert, M Walsh, V Tesar, R Becvar, P Horak, I Rychlik, W Szpirt, H Dieperink, J Gregersen, P Ivarsen, E Krarup, C Lyngsoe, C Rigothier, J Augusto, A Belot, D Chauveau, D Cornec, N Jourde-Chiche, M Ficheux, A Karras, A Klein, F Maurier, R Mesbah, O Moranne, A Neel, T Quemeneur, D Saadoun, B Terrier, P Zaoui, M Schaier, U Benck, R Bergner, M Busch, J Floege, F Grundmann, H Haller, M Haubitz, B Hellmich, J Henes, B Hohenstein, C Hugo, C Iking-Konert, F Arndt, T Kubacki, I Kotter, P Lamprecht, T Lindner, J Halbritter, H Mehling, U Schönermarck, N Venhoff, V Vielhauer, O Witzke, I Szombati, G Szucs, G Garibotto, F Alberici, E Brunetta, L Dagna, S De Vita, G Emmi, A Gabrielli, L Manenti, F Pieruzzi, D Roccatello, C Salvarani, M Harigai, H Dobashi, T Atsumi, S Fujimoto, N Hagino, A Ihata, S Kaname, Y Kaneko, A Katagiri, M Katayama, Y Kirino, K Kitagawa, A Komatsuda, H Kono, T Kurasawa, R Matsumura, T Mimura, A Morinobu, Y Murakawa, T Naniwa, T Nanki, N Ogawa, H Oshima, K Sada, E Sugiyama, T Takeuchi, H Taki, N Tamura, T Tsukamoto, K Yamagata, M Yamamura, P van Daele, A Rutgers, Y Teng, R Walker, I Chua, M Collins, K Rabindranath, J de Zoysa, M Svensson, B Grevbo, S Kalstad, M Little, M Clarkson, E Molloy, I Agraz Pamplona, J Anton, V Barrio Lucia, S Ciggaran, M Cinta Cid, M Diaz Encarnacion, X Fulladosa Oliveras, M Jose Soler, H Marco Rusinol, M Praga, L Quintana Porras, A Segarra, A Bruchfeld, M Segelmark, I Soveri, E Thomaidi, K Westman, T Neumann, M Burnier, T Daikeler, J Dudler, T Hauser, H Seeger, B Vogt, D Jayne, J Burton, R Al Jayyousi, T Amin, J Andrews, L Baines, P Brogan, B Dasgupta, T Doulton, O Flossmann, S Griffin, J Harper, L Harper, D Kidder, R Klocke, P Lanyon, R Luqmani, J McLaren, D Makanjuola, L McCann, A Nandagudi, S Selvan, E O'Riordan, M Patel, R Patel, C Pusey, R Rajakariar, J Robson, M Robson, A Salama, L Smyth, J Sznajd, J Taylor, P Merkel, A Sreih, E Belilos, A Bomback, J Carlin, Y Chang Chen Lin, V Derebail, S Dragoi, A Dua, L Forbess, D Geetha, P Gipson, R Gohh, G T Greenwood, S Hugenberg, R Jimenez, M Kaskas, T Kermani, A Kivitz, C Koening, C Langford, G Marder, A Mohamed, P Monach, N Neyra, G Niemer, J Niles, R Obi, C Owens, D Parks, A Podoll, B Rovin, R Sam, W Shergy, A Silva, U Specks, R Spiera, J Springer, C Striebich, A Swarup, S Thakar, A Tiliakos, Y Tsai, D Waguespack, M Chester Wasko Rheumatology, 2025 Objectives To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide. Methods In this descriptive, post hoc analysis, patients receiving avacopan or a prednisone taper were stratified by age. Key efficacy outcomes included the rate of remission at week 26 and sustained remission at week 52. Results Of 160 patients aged ≥65, 109 were aged 65–74 and 51 were ≥75. Remission at week 26 was achieved in 71.7% vs 69.4% of patients aged 65–74 and 73.1% vs 72.0% aged ≥75 in the avacopan vs prednisone taper groups, respectively. Sustained remission at week 52 was observed in 65.0% vs 55.1% of patients aged 65–74 and 65.4% vs 56.0% aged ≥75. Relapse rates in the avacopan vs prednisone taper groups were 12.3% vs 18.8% and 3.8% vs 20.8% in the 65–74 and ≥75 subgroups, respectively. Improvements in estimated glomerular filtration rate and health-related quality of life were observed in both treatment groups. Use of avacopan compared with a prednisone taper was associated with a 61% and 49% reduction in mean glucocorticoid dose in the 65–74 and ≥75 subgroups, respectively, and lower glucocorticoid toxicity. The proportions of patients with adverse events were similar between treatment groups within each age subgroup. Conclusion These data support the efficacy and safety of an avacopan-based regimen to treat patients with GPA or MPA aged ≥65.
The prognostic reasoning system for chronic kidney disease progression (PROGRES-CKD) may help improve waiting list management for outpatient nephrology services in a second-level public hospital in Italy Paolo Fabbrini, Federico Pieruzzi, Francesco Bellocchio, Raul Casana Eslava, Jordi Silvestre Llopis, Kevin Morillo Navarro, Paola Ferraresi, Len Usvyat, John Larkin, Jaroslav Rosemberg, Stefano Stuard, Luca Neri Journal of Nephrology, 2025 BACKGROUND: The management of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) is challenging due to coexisting diseases, competing risks and uncertainties around optimal transition planning. Such clinical challenges are further exacerbated by physician shortage, coupled with rising service demands, which may hinder timely medical access due to long waiting times. Accurate progression risk assessment may help optimize resource allocation and adapting care based on individual patients' needs. This study validated the Prognostic Reasoning System for Chronic Kidney Disease Progression (PROGRES-CKD) in an Italian public hospital and compared its potential impact on waiting list optimization against physician-based protocols. METHODS: First we first validated PROGRES-CKD by assessing its accuracy in predicting kidney replacement therapy (KRT) initiation within 6 months and 24 months in a historical cohort of patients treated at the San Gerardo Hospital (Italy) between 01-01-2015 and 31-12-2019. In a second study we compared PROGRES-CKD to attending nephrologists' prognostic ratings and simulated their potential impact on a waiting list management protocol. RESULTS: We included 2005 patients who underwent 11,757 outpatient nephrology visits in 4 years. Most visits occurred for NDD-CKD stage 4 patients; the incidence of KRT onset was 10.8 and 9.32/100 patient-years at the 6 and 24-month prediction horizon cohorts, respectively. PROGRES-CKD demonstrated high accuracy in predicting KRT initiation at 6 and 24 months (AUROC = 0.88 and AUROC = 0.85, respectively). Nephrologists' prognostic performance was highly operator-dependent, albeit always significantly lower than PROGRES-CKD. In the simulation exercise, allocation based on PROGRES-CKD resulted in more follow-up visits for patients progressing to end-stage kidney disease (ESKD) and fewer visits for non-progressing patients, compared to allocation determined by nephrologists' prognosis. CONCLUSIONS: PROGRES-CKD showed high accuracy in a real-world application. Waiting list simulation suggests that PROGRES-CKD may enable more efficient allocation of resources.
Improving the Annotation Process in Computational Pathology: A Pilot Study with Manual and Semi-automated Approaches on Consumer and Medical Grade Devices Giorgio Cazzaniga, Fabio Del Carro, Albino Eccher, Jan Ulrich Becker, Giovanni Gambaro, Mattia Rossi, Federico Pieruzzi, Filippo Fraggetta, Fabio Pagni, Vincenzo L’Imperio Journal of Imaging Informatics in Medicine, 2025 The development of reliable artificial intelligence (AI) algorithms in pathology often depends on ground truth provided by annotation of whole slide images (WSI), a time-consuming and operator-dependent process. A comparative analysis of different annotation approaches is performed to streamline this process. Two pathologists annotated renal tissue using semi-automated (Segment Anything Model, SAM)) and manual devices (touchpad vs mouse). A comparison was conducted in terms of working time, reproducibility (overlap fraction), and precision (0 to 10 accuracy rated by two expert nephropathologists) among different methods and operators. The impact of different displays on mouse performance was evaluated. Annotations focused on three tissue compartments: tubules (57 annotations), glomeruli (53 annotations), and arteries (58 annotations). The semi-automatic approach was the fastest and had the least inter-observer variability, averaging 13.6 ± 0.2 min with a difference (Δ) of 2%, followed by the mouse (29.9 ± 10.2, Δ = 24%), and the touchpad (47.5 ± 19.6 min, Δ = 45%). The highest reproducibility in tubules and glomeruli was achieved with SAM (overlap values of 1 and 0.99 compared to 0.97 for the mouse and 0.94 and 0.93 for the touchpad), though SAM had lower reproducibility in arteries (overlap value of 0.89 compared to 0.94 for both the mouse and touchpad). No precision differences were observed between operators (p = 0.59). Using non-medical monitors increased annotation times by 6.1%. The future employment of semi-automated and AI-assisted approaches can significantly speed up the annotation process, improving the ground truth for AI tool development.
Identification of Four New Mutations in the GLA Gene Associated with Anderson–Fabry Disease Monia Anania, Federico Pieruzzi, Irene Giacalone, Barbara Trezzi, Emanuela Maria Marsana, Letizia Roggero, Daniele Francofonte, Michele Stefanoni, Martina Vinci, Carmela Zizzo, Marcomaria Zora, Tiziana Di Chiara, Giulia Duro, Giovanni Duro, Paolo Colomba International Journal of Molecular Sciences, 2025
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA study Antonia Camporeale, Francesco Bandera, Maurizio Pieroni, Federico Pieruzzi, Marco Spada, Anna Bersano, Laura Econimo, Chiara Lanzillo, Marta Rubino, Renzo Mignani, Irene Motta, Iacopo Olivotto, Ilaria Tanini, Rea Valaperta, Kelvin Chow, Irene Baroni, Sara Boveri, Francesca Graziani, Silvia Pica, Lara Tondi, Marco Guazzi, Massimo Lombardi Journal of Medical Genetics, 2023
Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy Francesca Menniti-Ippolito, Alfonso Mele, Roberto Da Cas, Salvatore De Masi, Flavia Chiarotti, Massimo Fabiani, Giovanni Baglio, Giuseppe Traversa, Francesca Colavita, Concetta Castilletti, Mario Salomone, Carmine Zoccali, Piergiorgio Messa, Aldo Pietro Maggioni, Andrea Lorimer, Martina Ceseri, Ester Baldini, Francesca Bianchini, Laura Sarti, Andrea Mariano, Eva Alessi, Lorenzo Di Liberato, Luigi Amoroso, Nicola Spetrino, Milva Di Giovanni, Carlo Sapio, Irma Figlia, Roberto Pititto, Teresa Papalia, Rosita Greco, Francesca Leone, Francesco Maria D’Agostino, Mariangela Campolo, Maria Rosa La Gamba, Francesca Mallamaci, Vincenzo Panuccio, Giovanna Parlongo, Giuseppe Natale, Domenico Tramontana, Ivania Maria Figliano, Santo Vitiello, Anna Maria Frangiosa, Domenico Caserta, Pasqualina Acconcia, Nunzia Paudice, Alfonso De Maio, Salvatore Cascone, Marilina Siani, Mario Cioffi, Nataliya Romanyuk, Franca Pagnano, Antonio De Donato, Ersilia Satta, Alessandra Perna, Francesco Trepiccione, Alessandro Cerrone, Gianluca Garofalo, Giancarlo Marinelli, Roberta D’Amato, Enrico De Felice, Alfredo Vacca, Salvatore Coppola, Vincenzo Cuomo, Maria Palma Iavarone, Annalisa Ciotola, Vincenzo Puglia, Pio Granato, Carla Lamberti, Giorgio Capasso, Domenico Bonanno, Marco Ventre, Veronica Amendola, Fabio Cappabianca, Elena Mancini, Davide Ricci, Daniela Cecilia Cannarile, Roberta Benevento, Bianca Perciaccante, Alda Storari, Yuri Battaglia, Giovanni Piva, Giovanni Mosconi, Alessandra Spazzoli, Paolo Ferdinando Bruno, Katia Ambri, Barbara Veterani, Sara Signorotti, Marcora Mandreoli, Renato Mario Rapanà, Maria Teresa Benedetto, Laura Patregnani, Maddalena Zambelli, Gaetano Alfano, Mariacristina Gregorini, Silvia Mattei, Francesca Iannuzzella, Elena Pelizzaro, Luca Camparini, Giuseppe Battaglino, Dino Romanini, Antonio Irlando, Lojze Celik, Giuseppa Natale, Maria Cristina Torre, Ilaria Umbro, Nicola Pirozzi, Loredana Fazzari, Lucia Pantano, Antonio Paone, Marco Galliani, Veronica Baglio, Eleonora Moscaritolo, Sabrina Fierimonte, Maria De Cristofaro, Elena Nebuloso, Paolo Menè, Francesca Romana Festuccia, Giulia Talarico, Claudia Fofi, Maria Elena Bracaccia, Ernesto Anselmo Cioffi, Fabio Mazza, Pasquale Polito, David Micarelli, Roberto Addesse, Lida Tartaglione, Sandro Feriozzi, Francesca Romana Della Rovere, Natalia Chipilova, Micol Manzuoli, Paolo Sacco, Francesca Ansaldo, Chiara Bottaro, Sonia Marre, Francesc Viazzi, Valeria Falqui, Novella Conti, Angelica Parodi, Valentina Zanetti, Francesca Cappadona, Andrea Speciale, Giancarlo Mancuso, Monica Repetto, Emanuela Chiara Vigo, Cairo Montenotte, Anna Maria Murgia, Piero Ruggenenti, Patrizia Ondei, Carmela Giuseppina Condemi, Sivia Bernardi, Francesco Scolari, Paola Gaggia, Federico Alberico, Chiara Manenti, Brunella Valzorio, Corrado Camerini, Agnese Gallico, Michela Tonoli, Federico Daffara, Roberto Zubbani, Simona Guerini, Mattia Zappa, Nicole Zambetti, Alessandra Dalla Gassa, Paola Baldan, Luca Fraizzoli, Sergio Bisegna, Nicola Palmieri, Marco Petrilli, Giusy Mandanici, Francesca Serena Stefani, Valeria Ogliari, Cristina Tantardini, Fabio Malberti, Paola Pecchini, Vincenzo La Milia, Carlo Maria Guastoni, Annalisa Neri, Marina Cornacchiari, Marco Farina, Francesco Barbisoni, Milena Maggio, Mario Cozzolino, Matthias Cassia, Michela Frittoli, Lorenza Magagnoli, Rossella De Leonardis, Roberta Casazza, Simone Vettoretti, Emanuele Grimaldi, Matteo Abinti, Francesca Maria Ida Carminati, Silvia Giuliani, Matteo Benedetti, Nicholas Delfrate, Elisa Colombo, Angela Cervesato, Enrico Eugenio Minetti, Alberto Montoli, Chiara Brunati, Valerae Li Bergolis, Maurizio Galllieni, Cristina Airaghi, Monique Buskermolen, Laura Cosmai, Maria Antonietta Orani, Cristina De Salvo, Giuseppe Vezzoli, Giorgio Slaviero, Chiara Lanzani, Federico Pieruzzi, Gina Contaldo, Barbara Trezzi, Teresa Rampino, Fabrizio Grosjean, Paola Borille, Ciro Esposito, Giuseppe Sileno, Marta Arazzi, Gianvincenzo Melfa, Mariagiulia Tettamanti, Anna Tosetti, Marco D’Amico, Maria Giulia Magatti, Silvia Peiti, Luciano Pedrini, Annalisa Feliciani, Elena Pezzini, Silvio Volmer Bertoli, Daniele Ciurlino, Silvia Tedoldi, Vania Prettico, Giulia Maria Magni, Antonietta Gazo, Maurizio Nai, Silvia Muciaccia, Graziana Battini, Lino Merlino, Paola Casanova, Federica Lencia, Maddalena Ricci, Andrea Ranghino, Mauro Valente, Carolina Finale, Eleonora Guerrini, Marta Canonici, Stefano Santarelli, Rosa Maria Agostinelli, Marina Di Luca, Mauro Martello, Cristina Silvestri, Veronica Bertuzzi, Assunta Cardillo, Valentina Nastasi, Sara Belcastro, Marco Manganaro, Emanuele Luigi Parodi, Valentina Vaccaro, Antonella Giolito, Stefano Cusinato, Michele Battista, Elena Ragazzoni, Paola Marcella Carpani, Emanuele Stramignoni, Silvana Savoldi, Guido Martina, Chiara Deagostini, Marica Magnetti, Stefania Bussolino, Federica Ventrella, Sonia Santi, Marita Marengo, Daniela Falconi, Ilaria Serra, Luca Besso, Davide Diena, Doriana Chiari Notti, Paola David, Luciana Gravellone, Corrado Vitale, Silvia Berutti, Silvia Ganci, Federica Neve Vigotti, Giulio Cesano, Maurizio Borzumati, Patrizia Bio, Stefania Gioira, Oliviero Filiberti, Fabiola Pagani, Simonetta Ottone, Carlo Lomonte, Vincenzo Montinaro, Vito Pepe, Elisabetta Manno, Salvatore Di Paolo, Luigi Natalicchio, Carmela Gallo, Francesca Pansini, Rossella Varvara, Filomena D’Elia, NIcola Coviello, Concetta Prisciandaro, Lucia Vernò, Fernanda Misceo, Pierfelice Zazzera, Antonella Matrella, Loreto Gesualdo, Anna Maria Di Palma, Virginia Pronzo, Federica Cassone, Salvatore Di Paolo, Tiziana Piccolo, Dora Porcelluzzi, Antonella Di Franco, Mario Giannetto, Chiara Villani, Luigi Vernaglione, Angelo Specchio, Laura Stoico, Giovanni Stallone, Vincenzo Losappio, Barbara Infante, Luigi Morrone, Anna Lisa Marangi, Angela Rodio, Christian D’Altri, Paolo Venerito, Francesca Cianciotta, Filippo Aucella, Gaetano Ferrara, Anna Rachele Nardella, Luigi Francesco Pio Morrone, Maria Grazia Corallo, Giuseppina D’Ettorre, Francesco Caccetta, Davide Gianfreda, Antonello Pani, Gianfranca Cabiddu, Stefania Caria, Maria Maddalena Romano, Ciro Adamo, Giovanni Giorgio Battaglia, Barbara Pocorobba, Emanuela Prencipe, Margherita Saraceno, Luana Scuderi, Salvatore Randone, Francesca Bruno, Rossella Rita Marchese, Antonio Granata, Daniela Puliatti, Carmelita Marcantoni, Luca Zanoli, Ambra D’anca, Domenico Santoro, Guido Gembillo, Alfio Eduardo Giuffrida, Vincenzo Labbozzetta, Angelo Tralongo, Gioacchino Li Cavoli, Carmela Zaggarigo, Paolo Conti, Sofia Giovannini, Silvia Farsetti, Pietro Claudio Giovanni Dattolo, Aris Tsalouchos, Stefano Michelassi, Marco Gallo, Irene Bandor, Nadia Sami, Daniela Riccomi, Lorena Traversari, Maria Grazia Tabbi, Maria Luisa Bonincontro, Vera Bonell, Giuliano Brunori, Diana Zarantonello, Alessandro Laudon, Antonio Selvi, Stefania Santoni, Davide Massimiani, Davide Rossi, Lorenzo Calò, Barbara Rossi, Giuseppe Scaparrotta, Fulvio Fiorini, Valentina Iacono, Carlo Rugiu, Monica Slaviero, Maurizio Nordio, Riccarda Maria Puggia, Adriana Caberlotto, Flavio Scanferla, Vincenzo Casoria, Federica Gramegna, Gina Meneghel, Ilenia Filippi, Anna Giacomini, Claudio Ronco, Anna Giuliani, Sabrina Milan Manani, Monica Zanella, and Journal of Nephrology, 2023
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial Vibeke Strand, David R W Jayne, Audra Horomanski, Huibin Yue, Pirow Bekker, Peter A Merkel, Chen Au Peh, Aron Chakera, Bruce Cooper, Jagadeesh Kurtkoti, Daman Langguth, Vicki Levidiotis, Grant Luxton, Peter Mount, David Mudge, Euan Noble, Richard Phoon, Dwarakanathan Ranganathan, Angus Ritchie, Jessica Ryan, Michael Suranyi, Alexander Rosenkranz, Karl Lhotta, Andreas Kronbichler, Nathalie Demoulin, Christophe Bovy, Rachel Hellemans, Jean-Michel Hougardy, Ben Sprangers, Karl Martin Wissing, Christian Pagnoux, Sean Barbour, Soumeya Brachemi, Serge Cournoyer, Louis-Philippe Girard, Louis-Philippe Laurin, Patrick Liang, David Philibert, Michael Walsh, Vladimir Tesar, Radim Becvar, Pavel Horak, Ivan Rychlik, Wladimir Szpirt, Hans Dieperink, Jon Waarst Gregersen, Per Ivarsen, Elizabeth Krarup, Cecilie Lyngsoe, Claire Rigothier, Jean-Francois Augusto, Alexandre Belot, Dominique Chauveau, Divi Cornec, Noemie Jourde-Chiche, Maxence Ficheux, Alexandre Karras, Alexandre Klein, Francois Maurier, Rafik Mesbah, Olivier Moranne, Antoine Neel, Thomas Quemeneur, David Saadoun, Benjamin Terrier, Philippe Zaoui, Matthias Schaier, Urs Tobias Benck, Raoul Bergner, Martin Busch, Juergen Floege, Franziska Grundmann, Hermann Haller, Marion Haubitz, Bernhard Hellmich, Joerg Christoph Henes, Bernd Hohenstein, Christian Hugo, Christof Iking-Konert, Fabian Arndt, T Kubacki, Ina Kotter, Peter Lamprecht, Tom Lindner, Jan Halbritter, Heidrun Mehling, Ulf Schönermarck, Nils Venhoff, Volker Vielhauer, Oliver Witzke, Istvan Szombati, Gabriella Szucs, Giacomo Garibotto, Federico Alberici, Enrico Brunetta, Lorenzo Dagna, Salvatore De Vita, Giacomo Emmi, Armando Gabrielli, Lucio Manenti, Federico Pieruzzi, Dario Roccatello, Carlo Salvarani, Masayoshi Harigai, Hiroaki Dobashi, Tatsuya Atsumi, Shoichi Fujimoto, Noboru Hagino, Atsushi Ihata, Shinya Kaname, Yuko Kaneko, Akira Katagiri, Masao Katayama, Yohei Kirino, Kiyoki Kitagawa, Atsushi Komatsuda, Hajime Kono, Takahiko Kurasawa, Ryutaro Matsumura, Toshihide Mimura, Akio Morinobu, Yohko Murakawa, Taio Naniwa, Toshihiro Nanki, Noriyoshi Ogawa, Hisaji Oshima, Kenei Sada, Eiji Sugiyama, Tohru Takeuchi, Hirofumi Taki, Naoto Tamura, Tatsuo Tsukamoto, Kunihiro Yamagata, Masahiro Yamamura, Paulus Leon Arthur van Daele, Abraham Rutgers, Y.K. Onno Teng, Robert Walker, Ignatius Chua, Michael Collins, Kannaiyan Rabindranath, Janak de Zoysa, My Hanna Sofia Svensson, Bard-Waldum Grevbo, Synove Kalstad, Mark Little, Michael Clarkson, Eamonn Molloy, Irene Agraz Pamplona, Jordi Anton, Vicente Barrio Lucia, Secundino Ciggaran, Maria Cinta Cid, Montserrat Diaz Encarnacion, Xavier Fulladosa Oliveras, Maria Jose Soler, Helena Marco Rusinol, Manuel Praga, Luis Quintana Porras, Alfons Segarra, Annette Bruchfeld, Marten Segelmark, Inga Soveri, Eleni Thomaidi, Kerstin Westman, Thomas Neumann, Michel Burnier, Thomas Daikeler, Jean Dudler, Thomas Hauser, Harald Seeger, Bruno Vogt, James Burton, Reem Al Jayyousi, Tania Amin, Jacqueline Andrews, Laura Anne Baines, Paul Brogan, Bhaskar Dasgupta, Timothy William Ronald Doulton, Oliver Flossmann, Sian V. Griffin, Janice Marian Harper, Lorraine Harper, Dana Kidder, Rainer Klocke, Peter Charles Lanyon, Raashid Luqmani, John Stuart McLaren, David Osagie Makanjuola, Liza McCann, Anupama C. Nandagudi, Shilpa Selvan, Edmond O'Riordan, Mumtaz Patel, Rajan Kantilal Patel, Charles Dickson Pusey, Ravindra Rajakariar, Joanna C. Robson, Michael Robson, Alan David Salama, Lucy Smyth, Jan Sznajd, Joanne Taylor, Antonie G. Sreih, Elise Belilos, Andrew S. Bomback, Jeffrey Carlin, Yih Chang Chen Lin, Vimal K. Derebail, Serban Dragoi, Anisha Dua, Lindsy Forbess, Duvuru Geetha, Patrick Gipson, Reginald Gohh, Gregory Todd Greenwood, Steven T. Hugenberg, Richard A.H. Jimenez, Marwan Omar Kaskas, Tanaz Kermani, Alan J. Kivitz, Curry Koening, Carol A. Langford, Galina Marder, Amr Ahmed El-Huesseini Mohamed, Paul Monach, Nilda Roxana Neyra, Gregory W. Niemer, John Niles, Reginald Obi, Charles Owens, Deborah L. Parks, Amber S. Podoll, Brad Rovin, R Sam, William Julius Shergy, Arnold Lawrence Silva, Ulrich Specks, Robert Spiera, Jason M. Springer, Christopher Charles Striebich, Areena Swarup, Surabhi Thakar, Athan N. Tiliakos, Yong Tsai, Dia R. Waguespack, Mary Chester Wasko Lancet Rheumatology, 2023
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan Frank B. Cortazar, John L. Niles, David R.W. Jayne, Peter A. Merkel, Annette Bruchfeld, Huibin Yue, Thomas J. Schall, Pirow Bekker, C. Au Peh, A. Chakera, B. Cooper, J. Kurtkoti, D. Langguth, V. Levidiotis, G. Luxton, P. Mount, D. Mudge, E. Noble, R. Phoon, D. Ranganathan, A. Ritchie, J. Ryan, M. Suranyi, A. Rosenkranz, K. Lhotta, A. Kronbichler, N. Demoulin, C. Bovy, R. Hellemans, J. Hougardy, B. Sprangers, K. Wissing, C. Pagnoux, S. Barbour, S. Brachemi, S. Cournoyer, L. Girard, L. Laurin, P. Liang, D. Philibert, M. Walsh, V. Tesar, R. Becvar, P. Horak, I. Rychlik, W. Szpirt, H. Dieperink, J. Gregersen, P. Ivarsen, E. Krarup, C. Lyngsoe, C. Rigothier, J. Augusto, A. Belot, D. Chauveau, D. Cornec, N. Jourde-Chiche, M. Ficheux, A. Karras, A. Klein, F. Maurier, R. Mesbah, O. Moranne, A. Neel, T. Quemeneur, D. Saadoun, B. Terrier, P. Zaoui, M. Schaier, U. Benck, R. Bergner, M. Busch, J. Floege, F. Grundmann, H. Haller, M. Haubitz, B. Hellmich, J. Henes, B. Hohenstein, C. Hugo, C. Iking-Konert, F. Arndt, T. Kubacki, I. Kotter, P. Lamprecht, T. Lindner, J. Halbritter, H. Mehling, U. Schönermarck, N. Venhoff, V. Vielhauer, O. Witzke, I. Szombati, G. Szucs, G. Garibotto, F. Alberici, E. Brunetta, L. Dagna, S. De Vita, G. Emmi, A. Gabrielli, L. Manenti, F. Pieruzzi, D. Roccatello, C. Salvarani, H. Dobashi, T. Atsumi, S. Fujimoto, N. Hagino, A. Ihata, S. Kaname, Y. Kaneko, A. Katagiri, M. Katayama, Y. Kirino, K. Kitagawa, A. Komatsuda, H. Kono, T. Kurasawa, R. Matsumura, T. Mimura, A. Morinobu, Y. Murakawa, T. Naniwa, T. Nanki, N. Ogawa, H. Oshima, K. Sada, E. Sugiyama, T. Takeuchi, H. Taki, N. Tamura, T. Tsukamoto, K. Yamagata, M. Yamamura, P. van Daele, A. Rutgers, Y. Teng, R. Walker, I. Chua, M. Collins, K. Rabindranath, J. de Zoysa, M. Svensson, B. Grevbo, S. Kalstad, M. Little, M. Clarkson, E. Molloy, I. Agraz Pamplona, J. Anton, V. Barrio Lucia, S. Ciggaran, M. Cinta Cid, M. Diaz Encarnacion, X. Fulladosa Oliveras, M. Jose Soler, H. Marco Rusinol, M. Praga, L. Quintana Porras, A. Segarra, A. Bruchfeld, M. Segelmark, I. Soveri, E. Thomaidi, K. Westman, T. Neumann, M. Burnier, T. Daikeler, J. Dudler, T. Hauser, H. Seeger, B. Vogt, D. Jayne, J. Burton, R. Al Jayyousi, T. Amin, J. Andrews, L. Baines, P. Brogan, B. Dasgupta, T. Doulton, O. Flossmann, S. Griffin, J. Harper, L. Harper, D. Kidder, R. Klocke, P. Lanyon, R. Luqmani, J. McLaren, D. Makanjuola, L. McCann, A. Nandagudi, S. Selvan, E. O'Riordan, M. Patel, R. Patel, C. Pusey, R. Rajakariar, J. Robson, M. Robson, A. Salama, L. Smyth, J. Sznajd, J. Taylor, P. Merkel, A. Sreih, E. Belilos, A. Bomback, J. Carlin, Y. Chang Chen Lin, V. Derebail, S. Dragoi, A. Dua, L. Forbess, D. Geetha, P. Gipson, R. Gohh, G.T. Greenwood, S. Hugenberg, R. Jimenez, M. Kaskas, T. Kermani, A. Kivitz, C. Koening, C. Langford, G. Marder, A. Mohamed, P. Monach, N. Neyra, G. Niemer, J. Niles, R. Obi, C. Owens, D. Parks, A. Podoll, B. Rovin, R. Sam, W. Shergy, A. Silva, U. Specks, R. Spiera, J. Springer, C. Striebich, A. Swarup, S. Thakar, A. Tiliakos, Y. Tsai, D. Waguespack, M. Chester Wasko Kidney International Reports, 2023
Trabecular complexity as an early marker of cardiac involvement in Fabry disease Antonia Camporeale, Francesco Moroni, Davide Lazzeroni, Silvia Garibaldi, Maurizio Pieroni, Federico Pieruzzi, Paola Lusardi, Marco Spada, Renzo Mignani, Alessandro Burlina, Francesca Carubbi, Laura Econimo, Yuri Battaglia, Francesca Graziani, Silvia Pica, Kelvin Chow, Paolo G Camici, Massimo Lombardi European Heart Journal Cardiovascular Imaging, 2022
Radiation dose from medical imaging in end stage renal disease patients: a Nationwide Italian Survey Maurizio Postorino, Domenico Lizio, Andreana De Mauri, Carmela Marino, Giovanni Luigi Tripepi, Carmine Zoccali, Marco Brambilla, Emilio Balestra, Diego Bellino, Roberta Benevento, Cristina Bregant, Paola Bregant, Barbara Cannillo, Giuseppe Casto, Doriana Chiarinotti, Sara Cimolai, Giacomo Colussi, Antonio De Agostini, Fausto Declich, Maria Grazia Facchini, Maria Alessandra Galione, Cesare Gavotti, Ugo Gerini, Paola Isoardi, Cristina Izzo, Fabrizio Levrero, Eric Lorenzon, Stefano Maffei, Stefania Maggi, Alberto Mari, Federico Mattana, Alberto Menegotto, Ophelia Meniconi, Nicoletta Paruccini, Luisa Pierotti, Federico Pieruzzi, Giuseppe Pontoriero, Adele Postorino, Marco Quaglia, Osvaldo Rampado, Andrea Ranghino, Sonia Reccanello, Stefania Sabatino, Giulia Sangalli, Chiara Sottocornola, Marina Sutto, Salvatore Tata, Alberto Torresin, Antonio Traino, Annalisa Trianni, Letizia Zeni, and Journal of Nephrology, 2021
Ramipril and cardiovascular outcomes in patients on maintenance hemodialysis: The arcadia multicenter randomized controlled trial Piero Ruggenenti, Manuel Alfredo Podestà, Matias Trillini, Annalisa Perna, Tobia Peracchi, Nadia Rubis, Davide Villa, Davide Martinetti, Monica Cortinovis, Patrizia Ondei, Carmela Giuseppina Condemi, Carlo Maria Guastoni, Agnese Meterangelis, Antonio Granata, Emanuele Mambelli, Sonia Pasquali, Simonetta Genovesi, Federico Pieruzzi, Silvio Volmer Bertoli, Goffredo Del Rosso, Maurizio Garozzo, Angelo Rigotti, Claudio Pozzi, Salvatore David, Giuseppe Daidone, Giulio Mingardi, Giovanni Mosconi, Andrea Galfré, Giorgio Romei Longhena, Alfonso Pacitti, Antonello Pani, Jorge Hidalgo Godoy, Hans-Joachim Anders, Giuseppe Remuzzi, and Clinical Journal of the American Society of Nephrology, 2021
Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy Andrea Bernardini, Antonia Camporeale, Maurizio Pieroni, Federico Pieruzzi, Stefano Figliozzi, Paola Lusardi, Marco Spada, Renzo Mignani, Alessandro Burlina, Francesca Carubbi, Yuri Battaglia, Francesca Graziani, Silvia Pica, Lara Tondi, Kelvin Chow, Sara Boveri, Iacopo Olivotto, Massimo Lombardi Jacc Cardiovascular Imaging, 2020
MALDI imaging in Fabry nephropathy: a multicenter study Vincenzo L’Imperio, Andrew Smith, Antonio Pisani, Maria D’Armiento, Viviana Scollo, Stefano Casano, Renato Alberto Sinico, Manuela Nebuloni, Antonella Tosoni, Federico Pieruzzi, Fulvio Magni, Fabio Pagni Journal of Nephrology, 2020
Microscopic Polyangiitis Renato Alberto Sinico, Filippo Maria Sala, Maria Rosa Pozzi, Paolo Fabbrini, Federico Pieruzzi Rare Diseases of the Immune System, 2020
Kidney Involvement Renato Alberto Sinico, Fabio Pagni, Vincenzo L’Imperio, Valentina Binda, Paolo Fabbrini, Federico Pieruzzi, Gabriella Moroni Rare Diseases of the Immune System, 2020
Redefining the pulvinar sign in fabry disease S. Cocozza, C. Russo, A. Pisani, G. Olivo, E. Riccio, A. Cervo, G. Pontillo, S. Feriozzi, M. Veroux, Y. Battaglia, D. Concolino, F. Pieruzzi, R. Mignani, P. Borrelli, M. Imbriaco, A. Brunetti, E. Tedeschi, G. Palma American Journal of Neuroradiology, 2017
The putative role of MALDI-MSI in the study of Membranous Nephropathy Andrew Smith, Vincenzo L'Imperio, Elena Ajello, Franco Ferrario, Niccolò Mosele, Martina Stella, Manuel Galli, Clizia Chinello, Federico Pieruzzi, Goce Spasovski, Fabio Pagni, Fulvio Magni Biochimica Et Biophysica Acta Proteins and Proteomics, 2017
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis Sirio Cocozza, Gaia Olivo, Eleonora Riccio, Camilla Russo, Giuseppe Pontillo, Lorenzo Ugga, Silvia Migliaccio, Dario de Rosa, Sandro Feriozzi, Massimiliano Veroux, Yuri Battaglia, Daniela Concolino, Federico Pieruzzi, Antonino Tuttolomondo, Aurelio Caronia, Cinzia Valeria Russo, Roberta Lanzillo, Vincenzo Brescia Morra, Massimo Imbriaco, Arturo Brunetti, Enrico Tedeschi, Antonio Pisani Neuroradiology, 2017
ANCA-associated vasculitis in childhood: Recent advances Marta Calatroni, Elena Oliva, Davide Gianfreda, Gina Gregorini, Marco Allinovi, Giuseppe A. Ramirez, Enrica P. Bozzolo, Sara Monti, Claudia Bracaglia, Giulia Marucci, Monica Bodria, Renato A. Sinico, Federico Pieruzzi, Gabriella Moroni, Serena Pastore, Giacomo Emmi, Pasquale Esposito, Mariagrazia Catanoso, Giancarlo Barbano, Alice Bonanni, Augusto Vaglio Italian Journal of Pediatrics, 2017
Warped-average template technique to track on a cycle-by-cycle basis the cardiac filling phases on left ventricular volume Computers in Cardiology, 1998